RESULTS	In addition , metformin/colesevelam significantly reduced LDL-C ( -16.3 % ) , total cholesterol ( -6.1 % ) , non-high-density lipoprotein cholesterol ( -8.3 % ) , apolipoprotein B ( -8.0 % ) , and high-sensitivity C-reactive protein ( -17 % ) and increased apolipoprotein A-I ( +4.4 % ) and triglycerides ( +18.6 % ) versus metformin/placebo ( P < .01 for all ) .\